CompletedNCT03166501
Lanicemine for Hyperarousal in PTSD: A Placebo-Controlled Study
About this title
Read the official source — NCT03166501Medication studyAges 21–65United States
Understand this study
Who was this study for?
This study was for people with PTSD. Listed age limits: 21 years to 65 years. Other eligibility criteria applied.
- Listed locations
- HoustonSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: September 1, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 24
- Sponsor
- Baylor College of Medicine
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 21 Years to 65 Years
- Official registry ID
- NCT03166501
- Official title
Show the full official title
NMDA Receptor Modulation for Hyperarousal in PTSD
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Houston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Baylor College of Medicine, a university.
Did this study involve medication?
Yes. The study involved medication, including Lanicemine and Placebo.
Who was this study for?
This study was for people with PTSD. Listed age limits: 21 years to 65 years. Other eligibility criteria applied.
